Clinical trials
Hereditary Hemorrhagic Telangiectasia clinical trials
Below are recruiting hereditary hemorrhagic telangiectasia clinical trials, each written for real people, not researchers. We’re tracking 12 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07601425RecruitingPhase 1/Phase 2
ATV-1601 Treatment for Hereditary Hemorrhagic Telangiectasia
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
Boston, MassachusettsAges 18 years+ - NCT07623525RecruitingPhase 1/Phase 2
DIAG723 study for hereditary hemorrhagic telangiectasia
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
Camperdown, New South WalesAges 18 years+ - NCT04469517Recruiting
Study of low-oxygen factors in hereditary bleeding disorder
This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT04976036RecruitingPhase 2
Nintedanib to reduce nosebleeds in adults with HHT
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
BronAges 18 years+ - NCT05641142Recruiting
Testing blood thinners in adults with inherited bleeding vessel disease
This study looks at people with Rendu-Osler (hereditary hemorrhagic telangiectasia) who have just started blood-thinning medicines. It aims to understand how antiplatelet and/or anticoagulant therapy affects safety and outcomes soon after starting.
AngersAges 18 years+ - NCT06259292Recruiting
HHT patient registry tracking long-term outcomes
This registry collects health information from people with HHT over time to better understand the disease and improve care. Joining does not involve any experimental treatment, but your data will help researchers learn more about HHT.
Birmingham, AlabamaAges Any age - NCT00230620Recruiting
Study of inherited bleeding disorder genes in HHT families
This study looks at DNA (genetic material) in families affected by hereditary hemorrhagic telangiectasia (HHT). It aims to understand the genetic basis of HHT and why it runs in families.
LondonAges Any age - NCT00230685Recruiting
Review of case notes for people with HHT
This study reviews past medical records (case notes) from people with hereditary hemorrhagic telangiectasia (HHT). It helps researchers understand patterns of care and outcomes, without requiring new treatment for you.
LondonAges Any age - NCT07445347Enrolling by invitation
Bevacizumab for severe HHT liver issues with high heart output
This study looks at how well the drug Bevacizumab works and how safe it is for people with HHT who have severe liver problems that cause their heart to pump too much blood. It aims to help doctors understand if this treatment can help manage these serious symptoms.
PoitiersAges 18 years+ - NCT06261333Enrolling by invitation
Quality of life study for HHT patients
This study looks at how hereditary hemorrhagic telangiectasia (HHT) affects your day-to-day life and well-being. By joining, you'll answer questions to help doctors better understand the impact of the condition.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT06573723Recruiting
Rare disease registry at Hospital Italiano
This study collects information from patients with certain rare diseases to better understand them. If you have one of these conditions and receive care at Hospital Italiano de Buenos Aires, you may be able to join.
Buenos Aires, Buenos AiresAges Any age - NCT07414446Recruiting
Detecting lung blood flow issues with a new ultrasound device
This trial uses a non-invasive ultrasound device to detect abnormal blood flow connections in the lungs, which are common in people with hereditary hemorrhagic telangiectasia (HHT) or a type of stroke called cryptogenic stroke. The goal is to see if the device can find these issues safely and easily without needing an invasive procedure.
Nieuwegein, UtrechtAges 18 years+
Hear when a new Hereditary Hemorrhagic Telangiectasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hereditary hemorrhagic telangiectasia?
- Yes. Clin2 currently lists 12 recruiting hereditary hemorrhagic telangiectasia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hereditary hemorrhagic telangiectasia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hereditary hemorrhagic telangiectasia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.